Although immunohistochemistry does not significantly aid in distinguishing ANNUBP from neurofibromas, varying degrees of loss in S-100/SOX-10 expression and the CD34+ fibroblast network may correlate with tumor malignancy. Here, CD34 is linked to neurofibroma.